Transient intermediates in the radiolysis of hyaluronic acid.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M D Young.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Blood forms of human vivax malaria infected splenectomized night monkeys (Aotus trivirgatus). Anopheles albimanus mosquitoes transmitted the in fection from a monkey to two human volunteers; parasites and symptoms ap peared 11 days later. Blood forms of vivax malaria from each of the two humans infected other night monkeys.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Tocainide is an orally effective antiarrhythmic agent, structurally and pharmacologically similar to lidocaine. It appears to be free of marked negative hemodynamic or electrophysiologic effects in patients with heart disease, despite a high frequency of minor and often transient central nervous system and gastrointestinal side effects. Tocainide is effective in suppressing ventricular arrhythmias in a variety of settings. This agent may be a useful addition to our antiarrhythmic armamentarium.
Explore the source record for details and available documents.
In a prospective multicenter trial, 43 patients with acute duodenal ulcers unhealed after four weeks of treatment with an H2-receptor antagonist, ranitidine, were switched to treatment with another H2-receptor antagonist, cimetidine. Sixty-eight percent of the unhealed patients were successfully healed; of these patients, 81% were free of daytime pain and 89% were free of nighttime pain. Of those with residual pain, 71% and 50% showed improvement in daytime and nighttime pain severity, respectively. There were no unexpected adverse reactions reported or clinically significant changes in laboratory values measured during the study. It is concluded that cimetidine is highly effective both in healing duodenal ulcers unresponsive to ranitidine therapy and in providing continued relief of daytime and nighttime pain.
In a prospective multicenter trial, 88 patients with acute duodenal ulcers that were healed with ranitidine were randomly assigned to receive maintenance treatment with either cimetidine 400 mg (n = 45) or placebo (n = 43) at bedtime for six months. Ten percent of the patients experienced moderate or severe pain both during the day and at night while on placebo during the maintenance phase. The average proportion of cimetidine patients experiencing moderate or severe pain during the day or night was 50% and 80% lower than placebo, respectively. Ulcer-like symptoms prompted endoscopy in 44% (19 of 43) of the placebo patients compared with 18% (eight of 45) of patients receiving cimetidine (P = 0.009). At the completion of the maintenance study, cumulative symptomatic ulcer recurrence rates were 28% (12 of 43) for those on placebo compared with 13% (six of 45) for cimetidine patients. The adverse drug effects noted were similar between treatment groups, with no unexpected reactions reported. A low dose of cimetidine (400 mg) at bedtime effectively reduced the incidence of gastrointestinal symptoms that were severe enough to prompt endoscopy as well as the actual recurrence of ulcers in those patients who had responded to initial therapy with ranitidine, but who continued to be at increased risk of reulceration.
The technique of fluorescein angiography is described. Although Doppler studies and the arteriogram have been effective modalities in examining large vessel disease, no consistent means has been found to determine the extent of small vessel disease in the lower extremity. In this preliminary report, it is suggested by the authors that fluorescein angiography is an effective office-based procedure to evaluate the vascularity of the lower extremity.